Efficiency of tacrolimus therapy for perianal Crohn’s disease

Nanaeva, B. A.; Vardanyan, A. V.; Халиф, И. Л.

doi:10.17116/terarkh201587683-87

Search citation statements

Order By: Relevance

Paper Sections

Select...

Medical Management1

Citation Types

Supporting

Mentioning

Contrasting

Year Published

2018

2024

Publication Types

Select...

Article5

Relationship

Self Cite0

Independent5

Authors

Journals

Cited by 6 publications

(1 citation statement)

References 28 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…11 Topical tacrolimus has been shown to improve ulceration compared with placebo and reduce PCDAI score compared with bacterial suppositories and steroidal ointments in two small, randomized controlled trials. 12,13 Systemic therapies including steroids, antibiotics, aminosalicylates, and immunomodulators have shown inconsistent results. 5,12,[14][15][16] The gold standard for treatment of perianal CD is systemic anti-TNF medications, such as infliximab and adalimumab.…”

Section: Medical Managementmentioning

confidence: 99%

Nonfistulizing Perianal Crohn's Disease

Simon,

Steinhagen

2024

Clin Colon Rectal Surg

View full text Add to dashboard Cite

Perianal Crohn's disease (CD) includes a wide range of nonfistulizing sequela, including fissures and ulcers, skin tags, anal stricture, and anal cancer. Symptoms related to perianal manifestations of CD are often disabling and have a significant impact on patients' quality of life. They include pain, drainage, bleeding, difficulty with hygiene and may cause secondary difficulties with sexual and defecatory dysfunction. The care of patients with perianal CD requires a thoughtful approach, including detailed history taking, physical examination, and often multidisciplinary care teams to maximize quality of life and ameliorate symptoms.

show abstract